Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor We read the article by Ghassemi et al1 about the combination treatment with intravitreal melphalan hydrochloride and topotecan hydrochloride for resistant vitreous seeds with great interest. The 3 main practical concerns regarding the rationale for this therapy include the following: (1) the primary question, ie, does the need for such a regimen really exist? (2) the potential increased toxic effects of both drugs combined on the retina and photoreceptors; and (3) the risk of malignancy and surgery-related complications due to multiple injection sites.
Ramanjulu R, Palanivelu MS. Is Combination Therapy for Resistant Vitreous Seeds Really Essential?. JAMA Ophthalmol. 2015;133(2):231-232. doi:10.1001/jamaophthalmol.2014.4638